Back to School: How biopharma can reboot drug development. Access exclusive analysis here

1014 QT
BioCentury & Getty Images

Product Development

Oct. 14 Quick Takes: FDA approves first Ebola therapy; plus Vertex tumbles after hours on AAT discontinuation

Updates on Russia’s latest COVID-19 vaccine approval and more

Oct 15, 2020 | 2:08 AM GMT

Regenerons Ebola mAb cocktail approved
FDA approved Inmazeb atoltivimab/maftivimab/odesivimab-ebgn from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to treat Zaire ebolavirus infection. The mAb cocktail had raised the chance of survival vs. ZMapp,

Read the full 629 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers